Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur Rev Med Pharmacol Sci ; 21(15): 3402-3411, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28829501

RESUMO

OBJECTIVE: To investigate the expression levels of lncRNA HOXA11-AS in HCC tissues and cells, and to explore its biological role in the development and progression of HCC. PATIENTS AND METHODS: We detected the relative expression level of HOXA11-AS in 72 HCC tissues and cells by the real-time quantitative PCR (qRT-PCR) assay. After interference with HOXA11-AS expression in HCC cells, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), clone formation, flow cytometry and an established nude mice transplanted tumor model were used to detect the biological behavior of HCC cells. qRT-PCR and Western blotting assays were used to detect the expression level of large tumor suppressor kinases 1 (LATS1). The subcellular localization of HOXA11-AS in HCC was detected by separating nuclei from the cytoplasm. The molecular mechanism of HOXA11-AS was regulated by ribonucleoprotein immunoprecipitation-microarray (RIP-Chip) experiments. RESULTS: qRT-PCR assays showed that HOXA11-AS was relatively highly expressed in HCC tissues and cells. In vivo and in vitro experiments showed that HOXA11-AS could inhibit the proliferation of HCC cells, promote their apoptosis and retard the cell cycle progression from G1 to G0 phase. qRT-PCR and Western blotting assays results showed that LATS1 genes were the downstream target genes of HOXA11-AS. RIP and CHIP experiments showed that HOXA11-AS inhibited the expression of LATS1 genes by binding enhancer of zeste homolog 2 (EZH2) proteins. CONCLUSIONS: HOXA11-AS inhibited the malignant transcription of the LATS1 genes and promoted the malignant proliferation of HCC cells. Interactions among HOXA11-AS, PRC2, and LATS1 may provide a new target for the treatment of HCC.


Assuntos
Carcinoma Hepatocelular/metabolismo , Proteínas de Homeodomínio/farmacologia , Neoplasias Hepáticas/metabolismo , Proteínas Serina-Treonina Quinases/biossíntese , RNA Longo não Codificante/genética , Animais , Apoptose/efeitos dos fármacos , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/terapia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Citoplasma/metabolismo , Terapia Genética , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/terapia , Camundongos , Camundongos Nus , Transplante de Neoplasias , Proteínas Serina-Treonina Quinases/efeitos dos fármacos , Proteínas Serina-Treonina Quinases/genética , Interferência de RNA , RNA Interferente Pequeno
2.
Opt Lett ; 20(3): 291-3, 1995 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-19859164

RESUMO

An epitaxial Ba(2)NaNb(5)O(15) thin film with excellent crystalline properties has been achieved on a (001) KTiOPO(4) substrate by use of the technique of pulsed laser deposition. X-ray-diffraction analysis has revealed that (110)-oriented Ba(2)NaNb(5)O(15) film was produced. The film has good optical transmitting characteristics and a propagation loss as low as 1.08 dB/cm. The noncritical phase-matching feature in the second-harmonic generation process in the film waveguide has also been studied.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...